Published in Semin Liver Dis on February 19, 2010
TACE Combined With Iodine-125 Seeds Implantation for HCC | NCT03322280
Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57
Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol (2010) 5.87
Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization. PLoS One (2013) 1.63
Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis. BMC Gastroenterol (2013) 1.36
Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort. PLoS One (2012) 1.25
Liver resection and transplantation in hepatocellular carcinoma. Liver Cancer (2012) 1.24
Hepatocellular carcinoma: focus on different aspects of management. ISRN Oncol (2012) 1.21
Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma. World J Hepatol (2015) 1.17
Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis. PLoS One (2014) 1.15
Molecular pathology of hepatic neoplasms: classification and clinical significance. Patholog Res Int (2011) 1.14
Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J Gastroenterol (2010) 1.08
Role of stereotactic body radiation therapy for hepatocellular carcinoma. World J Gastroenterol (2014) 1.06
Evaluation of the new AJCC staging system for resectable hepatocellular carcinoma. World J Surg Oncol (2011) 1.06
Recent advances in the surgical treatment of hepatocellular carcinoma. World J Gastroenterol (2014) 1.06
HCC: current surgical treatment concepts. Langenbecks Arch Surg (2012) 1.03
Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma. World J Gastroenterol (2013) 1.02
Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via FOXO3a activation. Oncotarget (2015) 1.01
Changes of the liver volume and the Child-Pugh score after high dose hypofractionated radiotherapy in patients with small hepatocellular carcinoma. Radiat Oncol J (2012) 1.00
Hepatocellular carcinoma in a large medical center of China over a 10-year period: evolving therapeutic option and improving survival. Oncotarget (2015) 1.00
Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Curr Oncol (2011) 1.00
Management of hepatocellular carcinoma with portal vein thrombosis. World J Gastroenterol (2015) 0.98
Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma. Gut Liver (2013) 0.98
Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer (2013) 0.97
Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization. J Cancer Res Clin Oncol (2013) 0.96
Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of ≥ 3 cm. HPB (Oxford) (2014) 0.95
Hepatocellular carcinoma: a review. J Hepatocell Carcinoma (2016) 0.95
Pretreatment neutrophil-lymphocyte ratio: an independent predictor of survival in patients with hepatocellular carcinoma. Medicine (Baltimore) (2015) 0.95
Interventional therapies for hepatocellular carcinoma. Cancer Imaging (2012) 0.93
Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma. World J Hepatol (2013) 0.92
Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open (2016) 0.91
Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma. BMC Cancer (2013) 0.91
Scheduled interval trans-catheter arterial chemoembolization followed by radiation therapy in patients with unresectable hepatocellular carcinoma. J Korean Med Sci (2012) 0.90
Prognosis of hepatocellular carcinoma expressing cytokeratin 19: comparison with other liver cancers. World J Gastroenterol (2012) 0.90
C-reactive protein may be a prognostic factor in hepatocellular carcinoma with malignant portal vein invasion. World J Surg Oncol (2013) 0.90
Blood transfusion is associated with recurrence of hepatocellular carcinoma after hepatectomy in Child-Pugh class A patients. World J Surg (2015) 0.90
Molecular therapies in hepatocellular carcinoma: what can we target? Dig Dis Sci (2014) 0.89
Prognostic Role of Glasgow Prognostic Score in Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Medicine (Baltimore) (2015) 0.88
Branched-chain amino acid treatment before transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol (2012) 0.88
Applicability of the BCLC staging system to patients with hepatocellular carcinoma in Korea: analysis at a single center with a liver transplant center. Korean J Hepatol (2011) 0.87
Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study. Cancer Med (2015) 0.87
Symptom clusters and symptom interference of HCC patients undergoing TACE: a cross-sectional study in China. Support Care Cancer (2012) 0.87
Independent factors and predictive score for extrahepatic metastasis of hepatocellular carcinoma following curative hepatectomy. Oncologist (2012) 0.86
Transcatheter Arterial Chemoembolization With Gelatin Sponge Microparticles Treated for BCLC Stage B Hepatocellular Carcinoma: A Single Center Retrospective Study. Medicine (Baltimore) (2015) 0.86
Functional imaging techniques in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging (2012) 0.86
Neutrophil-to-lymphocyte ratio for the prognostic assessment of hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. Oncotarget (2016) 0.85
Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis. Oncologist (2015) 0.85
Actual 10-year survival following hepatectomy for hepatocellular carcinoma. HPB (Oxford) (2013) 0.84
Upregulation of microRNA-106b is associated with poor prognosis in hepatocellular carcinoma. Diagn Pathol (2014) 0.84
Expression of Potential Cancer Stem Cell Marker ABCG2 is Associated with Malignant Behaviors of Hepatocellular Carcinoma. Gastroenterol Res Pract (2013) 0.84
Does hepatic ischemia-reperfusion injury induced by hepatic pedicle clamping affect survival after partial hepatectomy for hepatocellular carcinoma? World J Surg (2013) 0.84
Solitary Large Hepatocellular Carcinoma: Staging and Treatment Strategy. PLoS One (2016) 0.84
Adipokines levels are associated with the severity of liver disease in patients with alcoholic cirrhosis. World J Gastroenterol (2015) 0.83
How grim is hepatocellular carcinoma? Ann Med Surg (Lond) (2014) 0.83
Prognosis evaluation in patients with hepatocellular carcinoma after hepatectomy: comparison of BCLC, TNM and Hangzhou criteria staging systems. PLoS One (2014) 0.83
Comparison of the effects of transarterial chemoembolization for advanced hepatocellular carcinoma between patients with and without extrahepatic metastases. PLoS One (2014) 0.83
Effects of statins on the risk of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) (2014) 0.82
Improving Outcomes with Surgical Resection and Other Ablative Therapies in HCC. Int J Hepatol (2011) 0.82
Clinical factors related to recurrence after hepatic arterial concurrent chemoradiotherapy for advanced but liver-confined hepatocellular carcinoma. J Radiat Res (2013) 0.82
Clinical course of sub-centimeter-sized nodules detected during surveillance for hepatocellular carcinoma. World J Gastroenterol (2012) 0.81
Expression of variant isoforms of the tyrosine kinase SYK determines the prognosis of hepatocellular carcinoma. Cancer Res (2014) 0.81
Recent advances in liver resection for hepatocellular carcinoma. Front Surg (2014) 0.81
Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma. Transl Oncol (2013) 0.81
Hong Kong Liver Cancer Staging System Is Associated With Better Performance for Hepatocellular Carcinoma: Special Emphasis on Viral Etiology. Medicine (Baltimore) (2015) 0.81
Serum Dickkopf-1 as a Biomarker for the Diagnosis of Hepatocellular Carcinoma. Yonsei Med J (2015) 0.80
Practice guidelines for ultrasound-guided percutaneous microwave ablation for hepatic malignancy. World J Gastroenterol (2013) 0.80
Grey zone in the Barcelona Clinic Liver Cancer Classification for hepatocellular carcinoma: Surgeons' perspective. World J Gastroenterol (2015) 0.80
An atypical age-specific pattern of hepatocellular carcinoma in Peru: a threat for Andean populations. PLoS One (2013) 0.80
Is there any benefit from expanding the criteria for the resection of hepatocellular carcinoma in cirrhotic liver? Experience from a developing country. World J Surg (2012) 0.80
A modified TNM-7 staging system to better predict the survival in patients with hepatocellular carcinoma after hepatectomy. J Cancer Res Clin Oncol (2013) 0.80
Hong Kong consensus recommendations on the management of hepatocellular carcinoma. Liver Cancer (2015) 0.80
Liver function impairment in liver transplantation and after extended hepatectomy. World J Gastroenterol (2013) 0.80
Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. World J Gastroenterol (2015) 0.80
Multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus - Eastern Hepatobiliary Surgical Hospital consensus statement. Oncotarget (2016) 0.79
Second Hepatectomy Improves Survival in Patients With Microvascular Invasive Hepatocellular Carcinoma Meeting the Milan Criteria. Medicine (Baltimore) (2015) 0.79
An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis. Nat Protoc (2015) 0.79
Metastatic hepatocellular carcinoma to parotid glands. Am J Case Rep (2014) 0.79
Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases. World J Gastroenterol (2013) 0.79
Cartilage oligomeric matrix protein: A novel non-invasive marker for assessing cirrhosis and risk of hepatocellular carcinoma. World J Hepatol (2015) 0.79
Transarterial chemoembolization vs. conservative treatment for unresectable infiltrating hepatocellular carcinoma: A retrospective comparative study. Mol Clin Oncol (2014) 0.79
Hepatocellular carcinoma and other malignancies in autoimmune hepatitis. Dig Dis Sci (2013) 0.79
Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. World J Gastroenterol (2015) 0.79
Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study. Oncotarget (2016) 0.78
Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients. Jpn J Clin Oncol (2015) 0.78
Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response. Oncotarget (2015) 0.78
Association of Histone Methyltransferase G9a and Overall Survival After Liver Resection of Patients With Hepatocellular Carcinoma With a Median Observation of 40 Months. Medicine (Baltimore) (2016) 0.78
Actionable gene expression-based patient stratification for molecular targeted therapy in hepatocellular carcinoma. PLoS One (2013) 0.78
Histone deacetylase 4 promotes cholestatic liver injury in the absence of prohibitin-1. Hepatology (2015) 0.78
Role of radiofrequency ablation in unresectable hepatocellular carcinoma: An Indian experience. Indian J Radiol Imaging (2013) 0.78
Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study. BMC Gastroenterol (2016) 0.78
Tolerability and efficacy of gamma knife radiosurgery on hepatocellular carcinoma with portal vein tumor thrombosis. Oncotarget (2016) 0.78
Clinical Practice Patterns of Radiotherapy in Patients with Hepatocellular Carcinoma: A Korean Radiation Oncology Group Study (KROG 14-07). Cancer Res Treat (2016) 0.78
Use of transient elastography to predict de novo recurrence after radiofrequency ablation for hepatocellular carcinoma. Onco Targets Ther (2015) 0.77
Survival of patients with hepatocellular carcinoma in the San Joaquin Valley: a comparison with California Cancer Registry data. Ann Gastroenterol (2012) 0.77
Antiviral therapies for hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol (2015) 0.77
Surgical Resection for Hepatocellular Carcinoma with Concomitant Esophageal Varices. World J Surg (2015) 0.77
The clinical effect and relevant mechanism of combined sorafenib and radiofrequency ablation in the treatment of early small hepatocellular carcinoma. Oncol Lett (2016) 0.77
Predictors of repeat transarterial chemoembolization in the treatment of hepatocellular carcinoma. HPB (Oxford) (2014) 0.77
Intermediate-stage hepatocellular carcinoma treated with hepatic resection: the NSP score as an aid to decision-making. Br J Cancer (2016) 0.77
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Hepatocellular carcinoma. Lancet (2003) 22.54
Hepatocellular carcinoma. Lancet (2012) 18.09
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet (2002) 12.16
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology (2003) 11.55
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology (2008) 6.75
Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol (2008) 5.24
Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol (2006) 5.17
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol (2013) 3.71
Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology (2015) 3.63
Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res (2012) 3.39
Management of HCC. J Hepatol (2012) 3.03
New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology (2013) 2.76
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology (2011) 2.66
The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl (2004) 2.65
Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology (2010) 2.61
Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology (2004) 2.54
Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol (2012) 2.53
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology (2013) 2.42
Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol (2011) 2.39
Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer (2009) 2.38
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32
Angiogenesis in liver disease. J Hepatol (2008) 2.31
Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology (2004) 2.29
Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology (2009) 2.10
Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol (2006) 1.98
MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology (2003) 1.85
Chemoembolization for intermediate HCC: is there proof of survival benefit? J Hepatol (2011) 1.84
Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers. Hepatology (2003) 1.80
Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology (2009) 1.79
MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology (2011) 1.77
Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star. Gastroenterology (2009) 1.70
IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol (2010) 1.66
High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl (2004) 1.65
A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology (2010) 1.64
Distinct cellular responses differentiating alcohol- and hepatitis C virus-induced liver cirrhosis. Virol J (2006) 1.58
Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol (2010) 1.49
The search for an effective partner for sorafenib: the failure of doxorubicin. Gastroenterology (2011) 1.45
Treatment of hepatocellular carcinoma. Crit Rev Oncol Hematol (2006) 1.45
Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res (2012) 1.44
Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma. Cancer Res (2003) 1.40
Non-invasive diagnosis of hepatocellular carcinoma ≤ 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. J Hepatol (2012) 1.37
Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. Hepatology (2012) 1.37
LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. Hepatology (2014) 1.31
Treatment of hepatocellular carcinoma: is there an optimal strategy? Cancer Treat Rev (2003) 1.25
Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Hepatology (2013) 1.19
A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer (2010) 1.15
HCC surveillance: who is the target population? Hepatology (2003) 1.12
Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--letter. Clin Cancer Res (2013) 1.12
Biopsy for liver cancer: how to balance research needs with evidence-based clinical practice. Hepatology (2015) 1.09
Biomarkers for early diagnosis of hepatocellular carcinoma. Lancet Oncol (2012) 1.02
Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. J Hepatol (2011) 1.01
Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. J Hepatol (2012) 1.01
Prognosis of hepatocellular carcinoma. Hepatogastroenterology (2002) 1.01
Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision. Liver Transpl (2003) 0.98
Diagnostic imaging and biopsy use among elderly medicare beneficiaries with hepatocellular carcinoma. J Oncol Pract (2011) 0.98
Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. J Hepatol (2013) 0.96
Prognostic prediction in patients with hepatocellular carcinoma. Semin Liver Dis (2005) 0.94
Abdominal drainage after liver resection for hepatocellular carcinoma in cirrhotic patients: a randomized controlled study. Hepatogastroenterology (2004) 0.92
Preoperative evaluation of biliary anatomy in adult live liver donors with volumetric mangafodipir trisodium enhanced magnetic resonance cholangiography. Liver Transpl (2004) 0.91
Treatment of early hepatocellular carcinoma: Towards personalized therapy. Dig Liver Dis (2010) 0.91
Orthotopic implantation of human hepatocellular carcinoma in mice: analysis of tumor progression and establishment of the BCLC-9 cell line. Clin Cancer Res (2004) 0.91
Treatment strategies for hepatocellular carcinoma in cirrhosis. J Gastrointest Surg (2003) 0.87
Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. Ann Saudi Med (2012) 0.87
p27(Kip1) is an independent predictor of recurrence after surgical resection in patients with small hepatocellular carcinoma. J Hepatol (2003) 0.86
Treatment of hepatocellular carcinoma. Dig Dis (2014) 0.85
New drugs for the treatment of hepatocellular carcinoma. Liver Int (2009) 0.85
Screening for liver cancer: the rush to judgment. Ann Intern Med (2012) 0.84
A DNA methylation signature associated with the epigenetic repression of glycine N-methyltransferase in human hepatocellular carcinoma. J Mol Med (Berl) (2013) 0.84
[Diagnosis and treatment of hepatocellular carcinoma]. Med Clin (Barc) (2009) 0.84
Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials. J Clin Oncol (2009) 0.83
Clinical management of hepatic malignancies: ferucarbotran-enhanced magnetic resonance imaging versus contrast-enhanced spiral computed tomography. Dig Dis Sci (2005) 0.83
Hepatocellular carcinoma in the setting of liver transplantation. Liver Transpl (2006) 0.82
Locoregional treatment for hepatocellular carcinoma: From clinical exploration to robust clinical data, changing standards of care. Hepatology (2008) 0.82
Ablation for hepatocellular carcinoma: Is there need to have a winning technique? J Hepatol (2010) 0.82
Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma. Eur J Gastroenterol Hepatol (2010) 0.82
Liver transplantation in hepatocellular carcinoma. Transpl Int (2005) 0.81
Multifaceted perspective of the waiting list for liver transplantation: the value of pharmacokinetic models. Hepatology (2010) 0.81
Expanded criteria for hepatocellular carcinoma through down-staging prior to liver transplantation: not yet there. Semin Liver Dis (2006) 0.81
Hepatocellular carcinoma in the United States. Lessons from a population-based study in Medicare recipients. J Hepatol (2005) 0.81
East meets the West--portal pressure predicts outcome of surgical resection for hepatocellular carcinoma. Nat Clin Pract Gastroenterol Hepatol (2008) 0.81
[Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers]. Med Clin (Barc) (2009) 0.81
Antiangiogenic therapy: not just for cancer anymore? Hepatology (2009) 0.81
Results of laparoscopic radiofrequency ablation for HCC. Could the location of the tumour influence a complete response to treatment? A single European centre experience. HPB (Oxford) (2014) 0.81
Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US. Radiology (2015) 0.80
Diagnosis of Small HCC. Gastroenterology (2005) 0.80
Liver cancer: An evolving challenge reaching research maturity. Hepatology (2008) 0.79
Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study. J Hepatol (2012) 0.79
Contrast-enhanced power Doppler sonography and helical computed tomography for assessment of vascularity of small hepatocellular carcinomas before and after percutaneous ablation. J Clin Ultrasound (2003) 0.79
Diagnosis and staging of hepatocellular carcinoma prior to transplantation: expertise or failure. Liver Transpl (2006) 0.79